Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy …
H Laurichesse, U Zimmermann, F Galtier… - Human Vaccines & …, 2012 - Taylor & Francis
In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX®)
can boost immunity against several diseases simultaneously. This Phase IIIb, parallel-group …
can boost immunity against several diseases simultaneously. This Phase IIIb, parallel-group …
Guidelines for the use of post-traumatic tetanus vaccines and passive immune preparation
CL Wang, S Liu, ZJ Shao, ZD Yin, QJ Chen… - … yu Fang yi xue za zhi …, 2019 - europepmc.org
Post-traumatic tetanus is the main type of non-neonatal tetanus. To reduce the incidence
and mortality rate of tetanus and guide the primary medical institutions to prevent and control …
and mortality rate of tetanus and guide the primary medical institutions to prevent and control …
Tetanus vaccination in the accident and emergency department
While tetanus is a rare disease in industrialized countries, this infectious disease is still
responsible for up to 1,000,000 deaths per year in the developing world. In Germany, the …
responsible for up to 1,000,000 deaths per year in the developing world. In Germany, the …
Combined diphtheria–tetanus–pertussis vaccine for tetanus-prone wound management in adults
T Hoel, JM Wolter, LM Schuerman - European Journal of …, 2006 - journals.lww.com
Methods A single-blind, randomized, controlled study of 320 healthy adults, the anti-tetanus
antibody response within 10 days following vaccination with Boostrix (reduced-antigen …
antibody response within 10 days following vaccination with Boostrix (reduced-antigen …
Tetanus: A potential public health threat in times of disaster
P Finkelstein, L Teisch, CJ Allen… - Prehospital and disaster …, 2017 - cambridge.org
Background: Tetanus is a potentially fatal condition that is rare in urban environments but is
seen in developing countries and post-natural-disaster. Therefore, the purpose of this report …
seen in developing countries and post-natural-disaster. Therefore, the purpose of this report …
Insufficient knowledge and inappropriate practices of emergency doctors towards tetanus prevention in trauma patients: a pilot survey
Y Liu, X Mo, X Yu, J Wang, J Tian… - Human Vaccines & …, 2020 - Taylor & Francis
China has a shocking number of tetanus cases in the world, but little research has
investigated doctors' knowledge of and practices in tetanus prophylaxis, especially tetanus …
investigated doctors' knowledge of and practices in tetanus prophylaxis, especially tetanus …
A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) …
B Thierry-Carstensen, K Jordan, HH Uhlving, T Dalby… - Vaccine, 2012 - Elsevier
BACKGROUND: Increasing incidence of pertussis in adolescents and adults has stimulated
the development of safe and immunogenic acellular pertussis vaccines for booster …
the development of safe and immunogenic acellular pertussis vaccines for booster …
Guidelines for the use of post-traumatic tetanus vaccines and passive immune preparation
CL Wang, S Liu, ZJ Shao, ZD Yin, QJ Chen… - Zhonghua liu Xing …, 2020 - europepmc.org
Post-traumatic tetanus is the main type of non-neonatal tetanus. To reduce the incidence
and mortality rateof tetanus and guide the primary medical institutions to prevent and control …
and mortality rateof tetanus and guide the primary medical institutions to prevent and control …
Evaluation of the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin administered as sham, postexposure prophylaxis of …
R Forrat, R Dumas, M Seiberling, M Merz… - Antimicrobial agents …, 1998 - Am Soc Microbiol
In a monocentric, double-blind, randomized trial, we examined the safety and
pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin (P-HTIG). As …
pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin (P-HTIG). As …
Immunogenicity and safety of a tetanus-diphtheria vaccine (adult type): clinical trial in adults
A Gil, R Dal-Ré, A González, L Lasheras… - Medicina …, 1995 - europepmc.org
Background The administration of tetanus-diphtheria vaccine (Td," adult" type) as booster
dose every ten years, instead of tetanus toxoid, is a usual practice in the US, and its is being …
dose every ten years, instead of tetanus toxoid, is a usual practice in the US, and its is being …